Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | GLA | P06280 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116246 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2116647 | 0.81 | ACP3 (0.41) | L3MBTL1PDE10A | |
| SCHEMBL27822129 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2116264 | 0.78 | PPARG (0.34) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2116374 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2116910 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2116735 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2120452 | 0.76 | FDPS (0.44) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL2118355 | 0.73 | PGK1 (0.51) | L3MBTL1 | |
| SCHEMBL2116629 | 0.73 | KDM4E (0.43) | KDM4EALDH1A1GLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | FDPS, GGPS1, CTPS1 | KDM4E 2805/4885ALDH1A1 1398/4885GLA 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.